23
Participants
Start Date
October 18, 2019
Primary Completion Date
July 27, 2021
Study Completion Date
July 27, 2021
Nivolumab
Specified Dose on Specified Days
Anastrozole
Specified Dose on Specified Days
Palbociclib
Specified Dose on Specified Days
Local Institution - 0011, Wilrijk
Local Institution, Liège
Local Institution, Namur
Local Institution - 0005, Elizabeth Vale
Breast Cancer Research Centre - WA, Nedlands
Local Institution - 0019, Marseille
Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg
Peninsula Cancer Institute, Newport News
Hosp Univer 12 De Octubre, Madrid
Hospital Universitario Virgen De La Victoria, Málaga
Northside Hospital,Inc.- Central Research Department, Atlanta
University Cancer Blood Ctr, Athens
Institut Claudius Regaud, Toulouse
Local Institution - 0075, Bordeaux
Centre de Cancerologie du Grand Montpellier, Montpellier
Hospital Universitario Virgen Del Rocio, Seville
Local Institution, Mönchengladbach
MetroHealth Medical Center, Cleveland
Klinik Essen-Mitte, Essen
Hospital Clinico Universitario De Valencia, Valencia
Local Institution, Bonn
Northwestern University, Chicago
Local Institution, Saarbrücken
Centre Leon Berard, Lyon
Local Institution - 0072, La Roche-sur-Yon
Local Institution - 0031, Whittier
Local Institution, Erlangen
Local Institution - 0073, Créteil
Local Institution - 0041, Florham Park
The Cancer Center At Hackensack University Medical Center, Hackensack
Local Institution - 0071, Ottawa
Local Institution - 0047, Monterrey Ponce
Local Institution - 0002, San Juan
Local Institution - 0062, San Juan
H. Univ. Vall dHebron, Barcelona
Local Institution - 0037, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY